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A therapeutic perspective for refractory polymyositis to corticosteroids 
and immunosuppressant drugs: A case report 
 








BACKGROUND: Polymyositis (PM) is a chronic, disabling, and progressive inflammatory disease with muscle and 
systemic involvement. Although it is uncommon, some patients may present drug resistance to initial treatment 
with corticosteroid and immunosuppressant drugs. 
CASE REPORT: In this study, a typical case of poor prognosis of a 40-year-old female with PM who presented 
resistance to the initial treatment with corticosteroids and immunosuppressants was presented. The first 
medication tested was prednisone for 30 days and then 5 pulses of methylprednisolone were performed for  
5 months, and since there was no effect, a combination of azathioprine and methotrexate was performed for  
8 months, which was also unsatisfactory. Then, the scheme was changed to cyclophosphamide, human 
immunoglobulin (HIG), and cyclosporine, which were also unable to change the clinical course of the disease, 
which led the prescriber to radically change the drug therapy to the immunobiological rituximab (RTX), the only 
medication capable of ensuring an excellent therapy response and recovery of muscle strength. 
CONCLUSION: This report demonstrates the importance of the necessary persistence for the prescriber to test 
certain classes and drug combinations in search of the best possible therapeutic response for the specific case, 
which only occurred after the prescription and proscription of the drugs of first choice and the change to the 
immunobiological drug, RTX. 
KEYWORDS: Polymyositis; Resistance; Corticosteroid; Immunosuppressant; Drugs; Rituximab 
 
Date of submission: 13 Mar. 2020, Date of acceptance: 22 Sep. 2020 
 
Citation: Junior DST. A therapeutic perspective for refractory polymyositis to corticosteroids and 
immunosuppressant drugs: A case report. Chron Dis J 2021; 9(1): 42-5. 
 
Introduction1 
Polymyositis (PM) is an inflammatory myopathy 
that constitutes a heterogeneous group of 
diseases characterized by proximal muscle 
weakness and serum elevation of enzymes 
originating from the skeletal musculature.1  
The etiology of PM remains unknown and its 
annual incidence is estimated to be less than 10 
cases per million individuals. Women are more 
affected in a ratio of approximately 2:1, with a 
bimodal peak of onset of the disease between  
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5-15 years and 45-65 years.2 
The course of the disease is variable and 
most patients respond satisfactorily to initial 
treatment with glucocorticoid and it is possible 
to identify other evolutionary patterns with an 
initial remission period followed by one or 
more episodes of recurrence, monocyclic or 
refractory to usual treatment.3 Among the 
factors of poor prognosis, it is highlighted in 
the initial diagnosis in the elderly, advanced 
degree of muscle weakness at the time of 
diagnosis, respiratory muscle dysfunction, 
presence of dysphagia, delay at the beginning 
of treatment after 6 months of onset of 
symptoms, and pulmonary or cardiac 
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The association of immunosuppressants and 
corticosteroid from the beginning of treatment 
should be performed in patients with poor 
prognostic factors since the number of patients 
who do not reach remission with isolated 
corticosteroid therapy is considerable.5-7 The 
response to immunosuppressants and 
corticosteroid will occur approximately 2-3 
months after the start of its use, and after this 
period with the optimized dose, if the patient 
still presents with clinical and laboratory signs of 
disease activity, and is not responding as 
expected, such a therapeutic scheme should be 
modified7. Among the cases treated at this 
rheumatology clinic, located in the northeast 
region of Minas Gerais, Brazil, we chose the only 
case of PM resistant to glucocorticoids (GCs) in 
follow-up in order to observe the similarities of 
the case described with the literature. 
Case Report 
This case report presented a 40-year-old woman 
diagnosed 11 years ago with PM, confirmed by 
muscle biopsy, electromyography, and muscle 
enzymes presented lameness and intense loss of 
strength of lower limbs and upper limbs. The 
first prescribed medication was prednisone, with 
daily dosing of 80 mg for 30 days, and 5  
pulses of methylprednisolone for 5 months. 
Then, the combination of azathioprine and 
methotrexate was tested for 8 months, which 
was not successful, modifying to intravenous 
cyclophosphamide with 1 dose every 4 weeks for 
about 8 months. However, the disease activity 
still maintained, which led to the change in the 
drug regimen for human immunoglobulin (HIG) 
with 5 daily doses and 1 monthly dose for  
9 months that was also unable to evolve to 
remission of the disease. Thus, the therapeutic 
regimen was replaced by 150 mg of cyclosporine 
daily, being 2 tablets of 50 mg in the morning 
and 1 tablet in the night for 7 months, not 
gaining good control of the disease again.  
Due to the weak therapeutic response to 
these conventional corticosteroid and 
immunosuppressant drugs presented in table 1, 
the prescriber suspended the previously tested 
therapeutic regimen and based on successful 
studies described in table 2, decided to 
experiment with rituximab (RTX), considering a 
second-line drug that was not widely used for 
the treatment of inflammatory myositis. 
 
Table 1. First choice drugs and posology for the 
conventional treatment of polymyositis (PM) 
Variables 
Prednisone: 5 and 20 mg tablets (maximum 80 mg/day); 
Methylprednisolone: powder for the injectable solution 
of 500 mg (administered 1000 mg intravenously over 1 
hour for 3 consecutive days); 
Azathioprine: 50 mg tablets (increasing 50 mg every 
two weeks to the total dose of 2-3 mg/kg/day); 
Methotrexate: 2.5 mg tablets or 25 mg/ml injectable 
solution (the dose may be increased to 25 mg/week); 
Cyclosporine: capsules of 10, 25, 50, 100 mg and oral 
solution of 100 mg/ml - 50 ml (up to a maximum dose of 
6 mg/kg/day); 
HIG: a vial of 0.5 g, 1 g, 2.5 g, 3 g, 5 g, and 6 g (1 
g/kg/day for 2 days or 0.4 g/   kg/day for 5 days, with a 
maximum dose of 70 g, repeated monthly for 3 to 6 
months in adults) 
Source: Clinical Protocol and Therapeutic Guidelines 
(Dermatomyositis and Polymyositis), revised in 2016 
HIG: Human immunoglobulin 
 
The medication regimen was changed to an 
intravenous infusion of 1,000 mg of RTX, with 
an interval of 14 days between doses, the same 
regimen used for the treatment of rheumatoid 
arthritis (RA). Before each administration of 
RTX, premedication was administered with 
antipyretic (paracetamol) and antihistamine 
(diphenhydramine) and methylprednisolone 
100 mg to decrease the incidence and severity 
of reactions to the infusion. The initial speed of 
the first infusion was 50 mg/hour. Thereafter, 
the speed was gradually increased by 50 
mg/hour every 30 minutes up to a maximum 
of 400 mg/hour.  
The patient did not present serious side 
effects to the administration of RTX, only 
nausea, mild headache, and fatigue in the 24 
hours after administration, however after the 
observation period, there was no more record 
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Table 2. Studies testing the response of patients with polymyositis (PM) to rituximab (RTX) therapy 
References Type of study Number of 
patients 
RTX dosage Outcome 
Valiyil et al.
8
 Moderate/large series/8 8 1 g I.V. at day 0 
and 14 
Improvement in muscle strenght 
and CK levels 
Gheita et at.
9
 Case report/1 1 500 mg I.V. at 
days 0 and 14 
Significant improvement in 
muscle and CK levels 
Mok et al.
10
 Open label/4 4 375 mg/m² weekly 
for 4 weeks 
Significant improvement in the 
mean proximal muscle power 





Case report/1 1 375 mg/m² weekly 
for 4 weeks 
Improvement in muscle strenght 
and CK levels 
CK: Creatine kinase 
 
The patient received an additional course of 
treatment 16 weeks after the first infusion for 
adequate control of the effect/response, in 
addition to ensuring the effectiveness and 
safety of maintaining the next therapeutic 
courses. The prognosis did not require  
dose adjustment during treatment and, after  
7 months of maintenance of the therapeutic 
course, the patient's health status remained 
satisfactory, with significant improvement in 
muscle strength and with a creatine kinase 
(CK) enzyme level of around 159.0 U/L, 
considered a normal value. 
Discussion 
Although in the present case study the use of 
glucocorticoid alone was not able to change 
the course of the PM favorably, the use of 
glucocorticoid can induce remission of the 
disease in approximately 40% to 60% of the 
patients. However, more than 80% present 
some degree of clinical and laboratory 
improvement with the treatment and patients 
should be informed that corticosteroid therapy 
may last longer than 12 months.6,7 
The variability of responses to the use of 
corticosteroids in the treatment of various 
inflammatory diseases is a known effect in the 
clinical setting. Although many patients present 
satisfactory responses to corticosteroid therapy, 
a small subpopulation of individuals fails to 
respond to the therapeutic effects of this class of 
medications. Based on this, patients can be 
classified as resistant to corticosteroids (RC).12 
The magnitude of the biological effects of these 
drugs is determined, among other factors, by 
the amount of target cell receptors and the 
receptor affinity to glucocorticoids.13 
In the evidence of disease activity (resistant 
disease), there is a need for increased or resumed 
glucocorticoid dose (relapsing disease), as well 
as intolerance to methotrexate or azathioprine, 
and should be considered a therapeutic 
modification. In this way, it is recommended to 
change the methotrexate by azathioprine or 
azathioprine association with methotrexate.14 
As in the case study, the association of 
azathioprine with methotrexate did not achieve 
the desired effect and pulse therapy was 
performed with methylprednisolone and should 
always be considered in cases of severe muscle 
weakness or severe systemic involvement.11 In 
the absence of response to the above measures, 
due to intolerance or relapse, it is recommended 
to replace the treatment previously used by 
cyclophosphamide, human immunoglobulin 
(HIG), or cyclosporine. The glucocorticoid 
should be maintained until control of disease 
activity. An option for resistant or intolerant 
patients to the drugs described is HIG.14-16 
Because it is an uncommon disease, PM drug 
therapy is based primarily on reports or series 
of cases. In general, the use of corticosteroids 
has been advocated as the drug of the first 
choice, and as a way to avoid these medications, 
several immunosuppressants are used as was 
used in the case described. However, a 
considerable number of patients do not respond 
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these cases, the immunobiological drug is used 
based on the pathophysiology of PM, especially 
RTX,17 the only therapeutic resource that was 
able to modify the course of the disease in the 
case studied. 
RTX is a chimeric monoclonal antibody 
directed against the CD20 antigen present on 
the surface of B cells. Its administration leads 
to selective depletion of CD20 + B 
lymphocytes.17 The experience of RTX therapy 
in the present case study was positive as it 
provided excellent disease control after  
6 months of use, which can be compared to the 
study by Valiyil et al.8 who observed 8 patients 
using 1 g I.V. of RTX on days 0 and 14, the 
study by Gheita et al. 9 who observed the case 
of 1 patient who used the 500 mg I.V. dosage 
on days 0 and 14, and the open study by Mok 
et al.10 with 4 patients and the case study by 
Belhassen-Garcia et al.11 with 1 patient, who 
used 375 mg/m² weekly for 4 weeks. All of 
these studies showed a satisfactory response, 
as did the present case study, with significant 
improvement in muscle strength and 
reduction in serum CK levels. 
Thus, immunobiological therapy with RTX 
played a crucial role in the control of refractory 
PM to conventional therapy. However, only with 
new prospective studies based on objective 
parameters of response to treatment can 
evidence be produced to justify such conduct.13 
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